Related Experiment Video
Updated: May 19, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Aneuploidy sensitizes cells to SREBP-pathway inhibition in squamous cell carcinoma
Nadja Zhakula-Kostadinova1,2, Sejal Jain3, Zeinab Amini-Farsani2
1Department of Genetics and Development, Columbia University Vagelos College of Physicians and Surgeons.
Abstract:
Squamous cell carcinomas (SCCs) in the lung, head and neck, cervix, and esophagus are characterized by widespread chromosome-arm aneuploidies, most frequently recurrent 3q-gain. However, how these alterations influence cancer development and therapeutic vulnerabilities remains unclear. To identify aneuploidy-driven therapeutic targets, we performed genome-wide CRISPR interference (CRISPRi) and drug-repurposing screens in isogenic immortalized lung epithelial cells harboring chromosome 3-disomy or 3q-gain. Both screens converged on a mevalonate pathway dependency specific to 3q-gain cells, which exhibited heightened sensitivity to sterol regulatory element-binding protein (SREBP) disruption. Rescue experiments demonstrated that these vulnerabilities were on target and that pathway inhibition preferentially causes apoptosis in 3q-gain cells. Transcriptomic and lipidomic profiling revealed 3q-gain-associated alterations in SREBP activation, cholesterol and fatty-acid biosynthesis, and lipid composition. Perturbing SREBP signaling impaired viability in SCC cell lines and suppressed tumor growth in xenografts with 3q-gain. These findings identify an aneuploidy-driven, targetable vulnerability in SCC.
Insights
Chromosome 3q-gain in squamous cell carcinomas (SCCs) creates a vulnerability in the mevalonate pathway. Targeting sterol regulatory element-binding protein (SREBP) signaling offers a new therapeutic strategy for SCCs.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Squamous cell carcinomas (SCCs) frequently exhibit chromosome-arm aneuploidies, notably 3q-gain.
- The functional impact of these aneuploidies on cancer development and therapeutic vulnerabilities is not well understood.
Purpose of the Study:
- To identify therapeutic targets driven by aneuploidy in SCCs.
- To investigate the role of chromosome 3q-gain in cellular dependencies and drug sensitivities.
Main Methods:
- Genome-wide CRISPR interference (CRISPRi) screens were conducted in isogenic lung epithelial cells with or without 3q-gain.
- Drug-repurposing screens were performed to identify compounds targeting 3q-gain-specific vulnerabilities.
- Transcriptomic and lipidomic profiling were used to analyze molecular alterations.
Main Results:
- Both screens identified a dependency on the mevalonate pathway specifically in 3q-gain cells.
- 3q-gain cells showed heightened sensitivity to sterol regulatory element-binding protein (SREBP) disruption.
- Inhibition of SREBP signaling impaired SCC cell viability and suppressed tumor growth in vivo.
Conclusions:
- Chromosome 3q-gain confers a specific vulnerability to SREBP-pathway inhibition in SCCs.
- This identifies an aneuploidy-driven, targetable liability for lipid-targeted precision therapies in squamous tumors.
Related Concept Videos
Nondisjunction
Abnormal Proliferation
Replicative Cell Senescence
Induced Pluripotent Stem Cells
Somatic cells are...
